Trial Profile
A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Drospirenone/estetrol (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Estetra SPRL
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society
- 06 Mar 2021 Results published in the Contraception
- 22 Jun 2018 Status changed from active, no longer recruiting to completed.